Resources

Navigating New U.S. Onshoring & Pharmaceutical Tariff Developments

Tech Transfer That Stays on Track: A 6 Month Path to Manufacturing Readiness

Quality by Design: How modern CDMOs build robust processes, analytical control, and regulatory confidence across the biologics lifecycle

From IND to BLA: Building a CMC Story That Holds Up at Approval

Conversations with Avid Experts: Building High-Performing Cell Lines for Biologic Therapies

Onshoring a Monoclonal Antibody in Phase 1 Clinical Trials at a 2000L Scale Achieving a Titer of 4 to 5 g/L

Designing for Scale: Choosing the Right CDMO for Late-Phase Success

Conversations with Avid Experts: Process Development as a Strategic Advantage in Biologic Manufacturing

From DNA to IND: A Practical Timeline for Advancing Your Program

Conversations with Avid Experts: How intensified purification approaches are improving efficiency, throughput, and cost-effectiveness

DNA to IND: An Early Phase Playbook for how to Build a CMC Strategy That Enables Fast IND

Seamless Onshoring from China-based CDMO to Avid Bioservices – Achieving a Titer of 5.2 g/L

Seven Forces Driving Onshoring in Biologics Manufacturing

Five Questions with Rich McAvoy: Scaling Avid with Discipline

Five Questions with Dave Stewart: Scaling Avid for What’s Next